Company intelligence / Profile preview

NovoThelium

San Antonio, Texas, United Statesnovothelium.com ↗

Ownership: Private
Development stage: Preclinical

Overview

NovoThelium is developing a decellularized donor-derived nipple–areolar matrix designed to enable patients’ own cells to regenerate a natural nipple following mastectomy. The technology has been tested in laboratory settings, with preclinical animal studies planned or ongoing. The company has won multiple innovation competitions and received grant funding but has not yet reported human clinical trial results[5][6].

Therapeutic areas: Women's HealthOncology
Modalities: Tissue-engineered matrixDecellularized tissue scaffoldRegenerative medicine product
Industry: Implantable Medical Devices

Partnerships

Academic collaborations with University of Texas at San Antonio[6]Collaborations with military research institutions[4]Engagements/interviews at MD Anderson Cancer Center[5]

Beyond the preview

Go deeper on NovoThelium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoThelium.

Explore the full profile